Table 4 Serum biochemical outcomes after atorvastatin treatment or placebo
Variables | Baseline | 8 weeks | Treatment difference, atorvastatin minus placebo (95% CI) | ||
|---|---|---|---|---|---|
| Â | Atorvastatin (n = 35) | Placebo (n = 32) | Atorvastatin & ICS (n = 32) | Placebo &ICS (n = 25) | Â |
Total cholesterol (mmol/l) | 5.15 (0.89) | 5.67 (1.12) | 3.62 (0.76) | 5.34 (0.90) | -1.55 (-1.88, -1.23) P < 0.0001 |
Triglycerides (mmol/l) | 1.59 (0.87) | 2.18 (1.41) | 1.02 (0.35) | 1.74 (1.29) | -0.49 (-0.87, -0.11) P = 0.013 |
LDL-cholesterol (mmol/l) | 3.19 (0.82) | 3.49 (0.99) | 1.89 (0.62) | 3.46 (0.87) | -1.50 (-1.88, -1.13) P < 0.0001 |
HDL-cholesterol (mmol/l) | 1.24 (0.35) | 1.26 (0.31) | 1.29 (0.35) | 1.23 (0.27) | 0.03 (-0.06, 0.13) p = 0.497 |
Alkaline phosphatase (IU/l) | 83.33 (31.36) | 75.16 (21.04) | 98.62 (91.26) | 77.16 (19.58) | 5.94 (-15.67, 27.54) p = 0.584 |
ALT (IU/l) | 17.58 (9.27) | 22.50 (11.88) | 22.00 (14.37) | 24.04 (11.70) | 3.67 (-1.84, 9.18) p = 0.188 |